Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant
Public ClinicalTrials.gov record NCT04368988. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 2-Part, Phase 1/2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-M™ Adjuvant In Healthy Subjects
Study identification
- NCT ID
- NCT04368988
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Novavax
- Industry
- Enrollment
- 1,419 participants
Conditions and interventions
Conditions
Interventions
- SARS-CoV-2 rS - Phase 1 Biological
- SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1 Biological
- Normal saline solution (NSS), Placebo - Phase 1 Other
- Normal saline solution (NSS), Placebo - Phase 2 Other
- SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1 Biological
- Normal saline solution (NSS), Placebo, Day 21 - Phase 1 Other
- SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2 Biological
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years to 84 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 24, 2020
- Primary completion
- May 31, 2022
- Completion
- May 31, 2022
- Last update posted
- Apr 9, 2023
2020 – 2022
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Meridian Clinical Research-(Savannah Georgia) - Platinum - PPDS - Phase 2 | Savannah | Georgia | 31406 | — |
| Advanced Clinical Research - Meridian - ERN-PPDS - Phase 2 | Meridian | Idaho | 83642 | — |
| Alliance for Multispecialty Research, LLC - Phase 2 | Newton | Kansas | 67114 | — |
| Alliance for Multispecialty Research, LLC - Phase 2 | Wichita | Kansas | 67207 | — |
| Central Kentucky Research Associates Inc - Phase 2 | Lexington | Kentucky | 40509 | — |
| Meridian Clinical Research-(Rockville Maryland) - Platinum - PPDS - Phase 2 | Rockville | Maryland | 20854 | — |
| Synexus Clinical Research US, Inc. - Cincinnati - Phase 2 | Cincinnati | Ohio | 45236 | — |
| Rapid Medical Research Inc - ERN-PPDS - Phase 2 | Cleveland | Ohio | 44122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04368988, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 9, 2023 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04368988 live on ClinicalTrials.gov.